source
- Madrigal’s 2024 MASH drug sparks new wave of diagnosis and personalized treatment approachesThe article argues that the field of metabolic dysfunction‑associated steatohepatitis (MASH) is entering a period of rapid innovation, and that the industry must broaden efforts in diagnosis, monit…
- RevMed stock rises on early Rasonque sales as whistleblower sues Madrigal over MASH safetyRevMed announced its first sales figures for Rasonque, a therapy targeting pancreatic cancer, and the news sent the company's shares higher. The company said the early sales data reflect market up…